Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Assets Average (2020 - 2025)

C4 Therapeutics (CCCC) has 6 years of Assets Average data on record, last reported at $312.3 million in Q4 2025.

  • For Q4 2025, Assets Average fell 13.93% year-over-year to $312.3 million; the TTM value through Dec 2025 reached $312.3 million, down 13.93%, while the annual FY2025 figure was $354.3 million, 2.39% down from the prior year.
  • Assets Average reached $312.3 million in Q4 2025 per CCCC's latest filing, up from $281.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $518.2 million in Q3 2021 and bottomed at $281.0 million in Q3 2025.
  • Average Assets Average over 5 years is $403.2 million, with a median of $387.2 million recorded in 2021.
  • Peak YoY movement for Assets Average: soared 61.25% in 2021, then decreased 25.78% in 2023.
  • A 5-year view of Assets Average shows it stood at $507.3 million in 2021, then decreased by 12.06% to $446.1 million in 2022, then decreased by 20.49% to $354.7 million in 2023, then increased by 2.28% to $362.8 million in 2024, then decreased by 13.93% to $312.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $312.3 million in Q4 2025, $281.0 million in Q3 2025, and $308.0 million in Q2 2025.